Verastem Reports Two-Year RAMP 201 Data in LGSOC
BOSTON — September 28, 2026 Verastem Oncology announced the publication in Gynecologic Oncology of two-year follow-up data from the...
cancer therapy
Advertisement
Persevere Therapeutics Doses First Patient in MIROC-1
CHESTERBROOK, Pa. — September 24, 2026 Persevere Therapeutics, Inc. announced that the first patient has been enrolled and treated...
Ionis and Roche Report Positive Phase 3 IgAN Results
Carlsbad, California, U.S., September 23, 2026 Ionis Pharmaceuticals, Inc. and partner Roche have announced positive prespecified interim results from...
Fullspan Health Launches AIQ for Pharma AI Search
New York, NY, U.S., September 22, 2026 Fullspan Health, a B2B healthcare platform backed by RVO Health, has launched...
Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
Advertisements
MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
Corcept Gains Positive CHMP Opinion for Lifyorli in Ovarian Cancer
REDWOOD CITY, Calif. — September 18, 2026 Corcept Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products...
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Telix and ITM Announce $1.65B Radiopharmaceutical Merger
Melbourne, Australia; Indianapolis, U.S.; Munich, Germany, September 21, 2026 Telix Pharmaceuticals Limited has announced a strategic agreement to lead...
MAIA Biotechnology Doses First U.S. Patient in THIO-101
CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...
Advertisement
